On Thursday, BD (Becton, Dickinson and Company) (NYSE:BDX) reported second-quarter sales of $5.04 billion, up 4.6% year over year, in line with the consensus. “Second quarter performance reflects our strategy in action and the strength of our diverse portfolio,” said Tom Polen, chairman, CEO and president of BD. “Our focus on BD Excellence and execution enabled strong operating margin and cash flow within the quarter. We enter the back half of fiscal 2024 with continued momentum giving us the confidence to again raise our fiscal 2024 earnings guidance as we deliver on our BD 2025 commitments.” Read Next: FDA Probe On China-Made Syringes: Becton Dickinson Boosts US Syringe Output Following Concerns. BD Medical segment sales increased $2.5 billion, ...